Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
The goal of this study is to evaluate the efficacy of HMPL-760 in combination with R-GemOx versus placebo in combination with R-GemOx in patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL).
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
DRUG: HMPL-760 planned dose 1|DRUG: R-GemOx|DRUG: HMPL-760 placebo planned dose 1|DRUG: HMPL-760 planned dose 2|DRUG: HMPL-760 placebo planned dose 2
Progression-free survival (PFS), Progression-free survival (PFS): Efficacy is evaluated using the Lugano Efficacy Evaluation Criteria for Malignant Lymphoma (Cheson 2014)., Up to approximately 2 years
Objective Response Rate (ORR), Objective Response Rate (ORR) is defined as the ratio of patients who reached complete response (CR) or partial response (PR), as assessed by investigator., Up to approximately 2 years|Complete response (CR) rate, Complete response (CR) rate is defined as the ratio of patients with who reached complete response (CR), as assessed by investigator., Up to approximately 2 years|Duration of response (DoR), For patients who reached complete response (CR) or partial response (PR), Duration of Response (DoR) is defined as the time from the first CR or PR until disease progression or death due to any cause, whichever occurs first, as assessed by investigator., Up to approximately 2 years|Clinical benefit rate (CBR), Defined as the ratio of patients with complete response (CR), partial response (PR), or stable disease (SD)., Up to approximately 2 years|Time to response (TTR), Time To Response (TTR) is defined as the time from the start of treatment to the first objective response rate (ORR), as assessed by investigator., Up to approximately 2 years|Overall survival (OS), Overall Survival (OS) is defined as the time from randomization to death due to any cause., Up to approximately 2 years|Safety Endpoints of adverse events, Incidence and severity of treatment-emergent adverse events (TEAEs), incidence of serious adverse events (SAEs), incidence of TEAEs leading to permanent discontinuation, dose interruption, and dose reduction, and their correlation to study drug. The severity is determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE 5.0)., Up to approximately 2 years|Pharmacokinetic(PK) profile of HMPL-760 in combination with R-GemOx, Trough plasma concentration (Ctrough) of drug, At the end of Cycle 7 (each cycle is 21 days)|Pharmacokinetic(PK) profile of HMPL-760 in combination with R-GemOx, Maximum observed concentration, occurring at time Tmax at steady-state (Cmax,ss) of drug, At the end of Cycle 7 (each cycle is 21 days)|Pharmacokinetic(PK) profile of HMPL-760 in combination with R-GemOx, Time of maximum observed concentration at steady-state(Tmax,ss) of drug, At the end of Cycle 7 (each cycle is 21 days)|Pharmacokinetic(PK) profile of HMPL-760 in combination with R-GemOx, The partial area from dosing time to dosing time plus Tau at steady-state (AUCss) of drug, At the end of Cycle 7 (each cycle is 21 days)|Pharmacokinetic(PK) profile of HMPL-760 in combination with R-GemOx, Apparent clearance at steady-state (CLss/F) of drug (if applicable), At the end of Cycle 7 (each cycle is 21 days)|Pharmacokinetic(PK) profile of HMPL-760 in combination with R-GemOx, Apparent volume of distribution at steady-state (Vz,ss/F) of drug (if applicable), At the end of Cycle 7 (each cycle is 21 days)
Biomarker assessment, To evaluate the correlation between potential biomarkers and the prognosis of patients treated with this regimen. Tumor tissue or blood samples will be examined to detect the gene expression of MYD88., Up to approximately 2 years|Metabolite analysis of HMPL-760 in combination with R-GemOx, Analysis metabolite of HMPL-760 in combination with R-GemOx, At the end of Cycle 7 (each cycle is 21 days)
A Phase II Randomized, Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HMPL-760 in Combination with R-GemOx versus Placebo in Combination with R-GemOx in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL). The study phases include screening period, treatment period, safety observation period, PFS follow-up period, and OS follow-up period.